Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

What Was Tested

The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This trial is registered with ClinicalTrials.gov, number NCT03882970, and is complete.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Hypoglycemic Agents, Insulin, Long-Acting, Internationality and Metformin.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

Results are reported in around 15 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Lancet (London, England)), a journal based in England.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.